These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 33602290)

  • 1. Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report.
    Kato T; Mizuno K; Nishio H; Yasui T; Hayashi Y
    J Med Case Rep; 2021 Feb; 15(1):86. PubMed ID: 33602290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Video-urodynamic effects of vibegron, a new selective β3-adrenoceptor agonist, on antimuscarinic-resistant neurogenic bladder dysfunction in patients with spina bifida.
    Aoki K; Momose H; Gotoh D; Morizawa Y; Hori S; Nakai Y; Miyake M; Anai S; Torimoto K; Tanaka N; Yoneda T; Matsumoto Y; Fujimoto K
    Int J Urol; 2022 Jan; 29(1):76-81. PubMed ID: 34608669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder.
    Kitta T; Chiba H; Kon M; Higuchi M; Kusakabe N; Ouchi M; Togo M; Abe-Takahashi Y; Tsukiyama M; Shinohara N
    J Pediatr Urol; 2022 Oct; 18(5):563-569. PubMed ID: 35965225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urodynamic effect of vibegron on neurogenic lower urinary tract dysfunction in individuals with spinal cord injury: A retrospective study.
    Matsuda K; Teruya K; Uemura O
    Spinal Cord; 2022 Aug; 60(8):716-721. PubMed ID: 35177800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vibegron, a Novel Potent and Selective β
    Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
    Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [EFFECTS OF COMBINATION THERAPY WITH VIBEGRON FOR ANTICHOLINERGIC-RESISTANT PEDIATRIC NEUROGENIC BLADDER].
    Yamamoto S; Hirano T; Nakamura C; Mori K; Hamano A
    Nihon Hinyokika Gakkai Zasshi; 2023; 114(3):81-85. PubMed ID: 39034119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of the novel β
    Yoshida M; Kakizaki H; Takahashi S; Nagai S; Kurose T
    Int J Urol; 2018 Jul; 25(7):668-675. PubMed ID: 29752752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
    Chen JV; Klein TM; Nesheim J; Mudd PN
    J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of paediatric neurogenic bladder: an approach in a resource-poor setting.
    Maison POM; Lazarus J
    Paediatr Int Child Health; 2017 Nov; 37(4):280-285. PubMed ID: 28714784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder.
    Kaga K; Yamanishi T; Kaga M; Fuse M; Kamasako T; Ishizuka M
    Int J Urol; 2020 Oct; 27(10):899-904. PubMed ID: 32767525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vibegron shows high efficacy in pediatric patients with refractory daytime urinary incontinence.
    Hyuga T; Tanabe K; Kubo T; Nakamura S; Nakai H; Moriya K
    Neurourol Urodyn; 2023 Apr; 42(4):794-798. PubMed ID: 36840745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact.
    Nitti V; Haag-Molkenteller C; Kennelly M; Chancellor M; Jenkins B; Schurch B
    Medicine (Baltimore); 2023 Jul; 102(S1):e32377. PubMed ID: 37499088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, for lower urinary tract dysfunction in mice with spinal cord injury.
    Shimizu N; Gotoh D; Nishimoto M; Hashimoto M; Saito T; Fujita K; Hirayama A; Yoshimura N; Uemura H
    Int J Urol; 2021 Oct; 28(10):1068-1072. PubMed ID: 34272910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study.
    Grigoleit U; Mürtz G; Laschke S; Schuldt M; Goepel M; Kramer G; Stöhrer M
    Eur Urol; 2006 Jun; 49(6):1114-20; discussion 1120-1. PubMed ID: 16542772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.
    McKeage K
    Clin Drug Investig; 2013 Jan; 33(1):71-91. PubMed ID: 23288694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
    BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of novel β
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Hashimoto K; Minemura K
    Int J Urol; 2019 Mar; 26(3):369-375. PubMed ID: 30557916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.
    Chen JV; Gahn JC; Nesheim J; Mudd PN
    Pharmacoeconomics; 2022 Oct; 40(10):979-988. PubMed ID: 35881325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies.
    Franco I; Hoebeke P; Baka-Ostrowska M; Bolong D; Davies LN; Dahler E; Snijder R; Stroosma O; Verheggen F; Newgreen D; Bosman B; Vande Walle J
    J Pediatr Urol; 2020 Apr; 16(2):180.e1-180.e8. PubMed ID: 32007426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
    Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
    J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.